| 货号 | AF4077-SP |
| 别名 | SML1; SML1trefoil factor 2, SML1, human spasmolytic polypeptide (SP)10spasmolytic protein 1; SP; Spasmolysin; Spasmolytic Polypeptide; trefoil factor 2 | 全称 | Trefoil Factor 2 |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) |
| 目标/特异性 | Detects human TFF2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 1% cross-reactivity with recombinant human TFF3 is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL |
| 来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 7032 (Human); 21785 (Mouse); 116592 (Rat) |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | E. coli-derived recombinant human TFF2 Glu24-Tyr129 Accession # Q03403 |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Trefoil factor 2 (TFF2), also known as spasmolytic polypeptide (Sp) is a 20 kDa secreted trefoil factor family protein. It is a protease-resistant glycoprotein primarily produced by mucous-secreting cells of the stomach and duodenum and is upregulated in response to inflammation. TFF2 interacts with mucin and other TFF2-binding proteins to protect and repair mucosal epithelium. TFF2 is also expressed by macrophages and lymphocytes and may have a role in modulating immune system responses. The 106 residue mature human TFF2 contains two trefoil domains (aa 36-72 and aa 80-121) and one N-linked glycosylation site. Human TFF2 shares 71% and 87% aa sequence identity with canine and mouse TFF2, respectively. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
Detection of Human TFF2 by Western Blot. Western blot shows lysates of human stomach tissue, human stomach cancer tissue, human breast tissue, and human kidney tissue. PVDF membrane was probed with 2 µg/mL of Goat Anti-Human TFF2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4077) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for TFF2 at approximately 19-21 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1. |
